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O-linked N -acetylglucosamine (O-GlcNAc) is a post-translational modification involving an
attachment of a single β-N-acetylglucosamine moiety to serine or threonine residues in
nuclear and cytoplasmic proteins. Cellular O-GlcNAc levels are regulated by two enzymes:
O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), which add and remove the modifica-
tion, respectively.The levels of O-GlcNAc can rapidly change in response to fluctuations in
the extracellular environment; however, O-GlcNAcylation returns to a baseline level quickly
after stimulus removal. This process termed O-GlcNAc homeostasis appears to be critical
to the regulation of many cellular functions including cell cycle progress, stress response,
and gene transcription. Disruptions in O-GlcNAc homeostasis are proposed to lead to the
development of diseases, such as cancer, diabetes, and Alzheimer’s disease. O-GlcNAc
homeostasis is correlated with the expression of OGT and OGA.We reason that alterations
in O-GlcNAc levels affect OGA and OGT transcription. We treated several human cell lines
with Thiamet-G (TMG, an OGA inhibitor) to increase overall O-GlcNAc levels resulting in
decreased OGT protein expression and increased OGA protein expression. OGT transcript
levels slightly declined with TMG treatment, but OGA transcript levels were significantly
increased. Pretreating cells with protein translation inhibitor cycloheximide did not stabilize
OGT or OGA protein expression in the presence of TMG; nor did TMG stabilize OGT and
OGA mRNA levels when cells were treated with RNA transcription inhibitor actinomycin
D. Finally, we performed RNA Polymerase II chromatin immunoprecipitation at the OGA
promoter and found that RNA Pol II occupancy at the transcription start site was lower
after prolonged TMG treatment. Together, these data suggest that OGA transcription was
sensitive to changes in O-GlcNAc homeostasis and was potentially regulated by O-GlcNAc.
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INTRODUCTION
O-linked N -acetylglucosamine (O-GlcNAc) is a post-
translational modification (PTM) first discovered by Gerald W.
Hart and Carmen-Rosa Torres in 1984 (1). They initially used
bovine milk galactosyltransferase (GalT1) to probe for terminal
N-acetylglucosamine glycoconjugates on T-cells and unexpect-
edly discovered the existence of single β-N -acetylglucosamine
conjugated proteins inside the cell (1). O-GlcNAc is a reversible
modification that is ubiquitiously expressed in higher eukaryotes.
O-GlcNAc transferase (OGT) is the enzyme that adds the O-
GlcNAc modification, whereas O-GlcNAcase (OGA) removes it
(2, 3). Because uridine diphosphate-N-acetyl-glucosamine (UDP-
GlcNAc), the end point of the hexosamine biosynthetic pathway,
is the high-energy donor substrate for OGT, O-GlcNAcylation
is sensitive to nutrient availability (4). Furthermore, the removal
and addition of O-GlcNAc termed O-GlcNAc cycling is highly
dynamic. Changes in hormones, nutrients, or the environment
cause within minutes to several hours changes to the total level of
O-GlcNAc on proteins (5–7). Importantly,O-GlcNAc cycling rates
affect transcription regulatory pathways, cell cycle progression,
and respiration (8–12).
Since O-GlcNAcylation plays a significant role in regulating a
wide panel of cellular processes, and aberrant O-GlcNAcylation
contributes to the development of diseases, understanding the
regulation of OGT and OGA is, therefore, important. Several stud-
ies report that the expression of OGT and OGA is sensitive to
changes in total cellular O-GlcNAc levels (13, 14). Elevation of O-
GlcNAc levels via pharmacological inhibition of OGA causes OGT
protein expression to decrease and OGA protein expression to
increase (13). A rapid decrease in OGA protein expression occurs
in mice embryonic fibroblasts when OGT is knocked out (14).
Cells appear to actively keep a specific level of O-GlcNAcylation
suggesting a certain homeostatic level of O-GlcNAc must be
maintained for optimal cellular function. Although alterations of
cellular O-GlcNAc levels affect OGT and OGA expression, the
exact mechanism as to explain this phenomenon is still unclear.
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An imbalance in the homeostasis of O-GlcNAc does contribute
to the development of diseases including cancer, diabetes, and
Alzheimer’s (15–18).
To further address how cells adjust OGT and OGA protein
expression in response to alterations in O-GlcNAc levels, we mea-
sured in different cell lines OGT and OGA protein and mRNA
expression and stability after pharmacologically inhibition of OGA
by Thiamet-G (TMG, an OGA inhibitor). In these experiments,
we were able to show that the OGA mRNA levels were more sensi-
tive compared to OGT to alterations inO-GlcNAc, and RNA Pol II
occupancy at the OGA transcription start site (TSS) was decreased
after prolonged TMG treatments. Altogether, our data show that
the protein expression of OGT and OGA is sensitive to changes in




All primary and secondary antibodies used for immunoblot-
ting were used at a 1:1,000 and 1:10,000 dilution, respectively.
Anti-O-linkedN -acetylglucosamine antibody [RL2] (ab2739) was
purchased from Abcam. Antibodies for OGT (AL-34) and OGA
(345) were gracious gifts from the Laboratory of Gerald Hart in
the Department of Biological Chemistry at the Johns Hopkins
University School of Medicine. Actin (A2066) antibody and anti-
chicken IgY HRP (A9046) were purchased from Sigma. Chromatin
immunoprecipitation (ChIP) grade mouse (G3A1) mAb IgG1
isotype control (5415) and RNA polymerase II antibody, clone
CTD4H8 (05-623) were purchased from Cell Signaling Technolo-
gies and Millipore, respectively. Anti-rabbit HRP (170-6515) and
anti-mouse HRP (170-6516) were purchased from Bio-Rad.
All reagents were purchased form Sigma unless otherwise
noted. Cycloheximide (CHX, C7698, Sigma) was used at 50µg/ml
for HeLa cells and 25µg/ml for K562 cells (19, 20). Actinomycin
D (AMD, A1410, Sigma) was used at 0.5µg/ml for HeLa cells and
5µg/ml for K562 cells (20, 21).
CELL CULTURE
HeLa cells and SH-SY5Y neuroblastoma cells were cultured in
DMEM (Invitrogen) supplemented with 10% fetal bovine serum
(FBS, Gemini) and 1% penicillin/streptomycin (Invitrogen). K562
cells were cultured in RPMI-1640 (Invitrogen) supplemented with
10% fetal bovine serum, 1×MEM non-essential amino acids solu-
tion (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 2.5 mM
HEPES, and 1% penicillin/streptomycin. Cells were treated with
10µM Thiamet-G (TMG, S.D. Specialty Chemicals) for 6, 8, 24,
or 48 h with fresh TMG supplied daily. Cells were also pretreated
with CHX for 4 h, followed by TMG treatment for 8 h or AMD for
0.5 h, followed by TMG treatment for 6 h. Cells were infected with
OGT, OGA, or green fluorescent protein (GFP) virus at a multi-
plicity of infection (MOI) of 75 for 24 h. After different treatments,
cells were harvested for western blot, quantitative PCR (qPCR), or
ChIP assay.
IMMUNOBLOTTING
Cells were lysed on ice for 30 min in Non-idet P-40 (NP-40) Lysis
Buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1 mM DTT, 40 mM GlcNAc, and 1% Non-idet P-40) with 1 mM
PMSF, 1 mM sodium fluoride, 1 mM β-glycerol phosphate, and
1× protease inhibitor cocktail I (leupeptin 1 mg/ml, antipain
1 mg/ml, benzamidine 10 mg/ml, and 0.1% aprotinin). Cell lysates
were mixed with 4× protein solubility mixture (100 mM Tris-
HCl, pH 6.8, 10 mM EDTA, 8% SDS, 50% sucrose, 5% β-
mercaptoethanol, 0.08% Pyronin-Y). All electrophoresis was per-
formed with 4–15% gradient polyacrylamide gels (Criterion Gels,
Bio-Rad) and separated at 120 V, followed by transfer to PVDF
membrane (Immobilon, Millipore) at 0.4 A. Blots were blocked
by 3% BSA in TBST (25 mM Tris-HCl, pH 7.6, 150 mM NaCl,
0.05% Tween-20) at room temperature for 20 min, then incu-
bated with primary antibody at 4°C overnight. After washing with
TBST for 5× 5 min, blots were incubated with HRP-conjugated
secondary for 1 h at room temperature, then washed with TBST
again and developed using chemiluminescent substrate (HyGlo
E2400; Denville Scientific). Blots were stripped in 200 mM glycine,
pH 2.5 at room temperature for 1 h and probed with different
primary antibodies. All immunoblotting results were repeated
in three independent experiments (9). OGA and OGT rela-
tive protein levels were measured by analyzing the bands den-
sity using ImageJ 1.48 (http://imagej.nih.gov/ij/download.html)
then normalized to the density of actin. All experiments were
repeated three times, and average relative fold changes were
calculated.
TOTAL RNA ISOLATION AND RT-PCR
Total RNA was isolated by TRI reagent solution (AM9738,
Ambion) according to manufacture’s instruction. Briefly, 2× 106
cells were resuspended by 1 mL TRI reagent solution. Then, 200µl
of chloroform was added to extract RNA. After spinning down,
upper phase containing total RNA was collected and incubated
with equal amount isopropanol. RNA pellets were then precipi-
tated by centrifugation, washed once with 70% ethanol, air-dried,
and dissolved in nuclease free water (Invitrogen).
RNA concentration was measured by Nanodrop 2000c
(Thermo) and 1µg of total RNA was used for reverse transcrip-
tion (RT) using iScript Reverse Transcription Supermix (170-8841,
Bio-Rad) following manufacturer’s instruction. In all,10µl of each
completed reaction mix was incubated in a thermal cycler (Model
2720, Applied Biosystems) using the following protocol: priming
5 min at 25°C, RT 30 min at 42°C, and RT inactivation 5 min at
85°C. cDNA products were diluted with 90µl nuclease free water
and analyzed by qPCR. All qPCR results were repeated in three
independent experiments (22).
ChiP ASSAY
K562 cells were harvested by centrifugation at 1,000 g for 5 min and
washed twice with 1× PBS. Cells were then crosslinked by 2 mM
EGS (21565, Pierce) in PBS at room temperature for 30 min, fol-
lowed by 1% formaldehyde (BP531-25, Fisher) for another 10 min.
Crosslinking reaction was terminated by 125 mM glycine. Cell pel-
lets were collected and lysed on ice for 30 min by cell lysis buffer
(10 mM Tris-HCl, pH 8.1, 10 mM NaCl, 0.5% NP-40) with pro-
tease inhibitors. Chromatin was collected by spinning down, and
the pellets were resuspended in cold nuclear lysis buffer (50 mM
Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS, 25% glycerol) with
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protease inhibitors. In total, 300 µl of nuclear lysis buffer was
used to resuspend chromatin from 2× 106 cells.
Chromatin DNA was sheared to the size of 100–300 bp by
sonication (Model Q800R, Active Motif) with the following pro-
tocol: amplification 75%, pulse on 15 s, pulse off 45 s, temperature
3°C. 200µl of sheared chromatin was diluted by adding 1 ml of
ChIP buffer (20 mM Tris-HCl pH8.1, 1.2% Triton X-100, 1.2 mM
EDTA, 20 mM NaCl) with protease inhibitors. 2µg of control IgG
and specific antibody were added to diluted chromatin respec-
tively, followed by end to end rotation at 4°C overnight. At the
same time, 12µl of diluted chromatin was saved as input and
processed later. Next day, 30µl of PBS washed M-280 Sheep Anti-
Mouse IgG Dynabeads (11204D, Invitrogen) was added to the
chromatin, followed by rotating at 4°C for 4 h. Dynabeads were
separated by DynaMag-2 Magnet (12321D, Invitrogen) and sub-
sequently washed with 1 ml of the following buffer for 5 min at
4°C: wash buffer 1 (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris-HCl pH 8.0, 150 mM NaCl), wash buffer 2 (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 300 mM
NaCl), wash buffer 3 (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris-HCl pH 8.0, 500 mM NaCl), wash buffer 4 (0.25 M
LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM
Tris-HCl pH 8.0), and TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM
EDTA).
Complexes were eluted from beads with 500µl elution buffer
(1% SDS,0.1 M NaHCO3, 40 mM Tris-HCl,pH 8.0,10 mM EDTA)
and added with 200 mM NaCl. Eluates and inputs were treated at
the same time with RNase A (EN0531, Thermo) at 65°C overnight,
followed by proteinase K (25530-031, Invitrogen) treatment for
2 h. DNA was extracted by phenol/chloroform/isoamyl alcohol
(AC327111000, Fisher) and precipitated by glycogen (10814-010,
Invitrogen) and ethanol (23). DNA pellets were air-dried,dissolved
in 50µl nuclease free water, and analyzed by qPCR.
qPCR ASSAY
cDNA or ChIP DNA samples were analyzed by qPCR using SsoAd-
vanced Universal SYBR Green Supermix (172-5271, Bio-Rad)
according to manufacturer’s instruction. Briefly, 2µl of cDNA or
5µl of ChIP DNA samples, SYBR green supermix, nuclease free
water, and primers (Table 1) for the target gene were mixed with
a total reaction volume of 20µl. A 96-well PCR plate (AVRT-LP,
Midsci) with the mixture was loaded to CFX96 Touch Real-Time
PCR Detection System (185-5195, Bio-Rad) with the following
protocol: polymerase activation and DNA denaturation 30 s at
95°C, amplification denaturation 5 s at 95°C and annealing 30 s
at 60 or 62°C with 40 cycles, and melt curve 65–95°C with 0.5°C
increment 5 s/step.
DATA ANALYSIS
Quantification cycle (Cq) value was recorded by CFX Manager™
software. For cDNA qPCR data, dynamic range of RT and ampli-
fication efficiency was evaluated before using ∆∆Cq method to
calculate relative gene expression change. For ChIP DNA qPCR
data, Cq value was normalized to percentage of input. Data
generated in three independent experiments was presented as
means± standard error and analyzed using two-tailed Student’s
t -test with P < 0.05 as significant difference.
Table 1 | Primer sequences used for qPCR.







−1000 OGA TSS Forward: TTGGGTCTCCTTGCTGTATG
Reverse: ACCTCACAGGTTGAGATAGATTT
OGA TSS Forward: GGGCTAGCCTATTAAGCTTCTTTA
Reverse: AGGGTGGCAAGCAGAAAT
+2700 OGA TSS Forward: TCCTTTCAGAGTTGCTCCAATA
Reverse: CAGTCAACCGAAACCATGAAC
RESULTS
ALTERATION IN O-GLcNAc LEVELS CHANGES THE PROTEIN
EXPRESSION OF OGT AND OGA
Previous reports demonstrated that different pharmacological
inhibitors of OGA, PUGNAc and GlcNAc-thiazoline, rapidly
increase the protein expression of OGA (13, 24). We explored
this phenomenon using another highly selective inhibitor of
OGA Thiamet-G (TMG) (25). We altered the O-GlcNAc levels
of SH-SY5Y neuroblastoma, HeLa cervical carcinoma, and K562
leukemia cells with TMG and measured O-GlcNAc, OGT, and
OGA levels at various time points up to 48 h of TMG treatment.
The O-GlcNAc levels were increased in the TMG treated sam-
ples while the pattern of O-GlcNAcylation was unique to each
of the three cells lines used. OGA protein expression increased
while OGT protein expression decreased gradually in the pro-
longed TMG treatment time points (Figures 1A–C). Additionally,
in SY5Y cells, we used adenoviral-mediated OGT or OGA infec-
tion to alter O-GlcNAc levels. GFP was used as a control for the
adenoviral infection. Cells overexpressing OGT showed an ele-
vation in O-GlcNAc levels and a slight increase in OGA protein
expression compared to control, while cells overexpressing OGA
showed a decrease inO-GlcNAc levels and a slight increase in OGT
protein expression compared to control (Figure 1D).
TMG DOES NOT STABILIZE OGA PROTEIN EXPRESSION
In order to explore the reason why TMG increases OGA protein
level, we asked the question does TMG increase OGA protein sta-
bility. We pretreated cells with CHX to inhibit protein translation
(26). We treated HeLa (Figure 2A) and K562 (Figure 2B) cells
with TMG and observed a robust increase in OGA protein level
(Figures 2A,B, Lane 2) compared to control cells without any
treatment (Figures 2A,B, Lane 1). When HeLa cells were treated
with CHX, OGT protein levels dramatically decreased compared
to control, and we did not observe much of a decrease in OGA pro-
tein expression (Figure 2A, Lane 3). However, both OGT and OGA
protein levels were dramatically decreased after CHX treatment in
K562 cells (Figure 2B, Lane 3) compared to control. Combination
of CHX and TMG did not change the OGA or OGT protein levels
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FIGURE 1 | OGA protein level was increased afterTMG treatment.
(A) SH-SY5Y neuroblastoma cells. (B) HeLa cervical cells. (C) K562
leukemia cells were treated with 10µM TMG for indicated time.
(D) SH-SY5Y cells were infected with GFP, OGT, and OGA adenovirus at 75
MOI for 24 h. Cells were lysed, overall O-GlcNAc level, OGA and OGT
protein level were analyzed by western blot with actin as a loading control.
Average fold change for OGT and OGA is listed on the blots.
(Figures 2A,B, Lane 4) compared to CHX treatment only suggest-
ing that the TMG mediated increase in OGA protein expression
was not due to increased stability of the protein.
OGA TRANSCRIPT LEVEL IS INCREASED AFTER TMG TREATMENT
Next, we investigated if OGT or OGA transcript level was altered
after TMG treatment. We analyzed OGA mRNA level in SH-SY5Y
(Figure 3A), HeLa (Figure 3B), and K562 (Figure 3C) cells. We
found OGA mRNA level increased from 6 h TMG treatment in all
three cell lines and was still elevated above control after 48 h TMG
treatment (Figures 3A,C). The OGA mRNA level corresponded
with the increase in protein level in Figure 1. However, the OGT
mRNA level did not significantly change (Figures 3D–F). We also
demonstrated that the corresponding OGA and OGT mRNA levels
increased slightly but not significantly when OGT or OGA were
overexpressed in SH-SY5Y cells (Figures 3G,H).
TMG DOES NOT STABILIZE OGA mRNA
Next, we asked the question whether increased OGA mRNA
level after TMG treatment was due to stabilized OGA mRNA.
AMD, a RNA synthesis inhibitor, was used to test OGA mRNA
stability. TMG treated HeLa cells showed an increase of OGA
mRNA level compared to control cells without any treatment
(Figure 4A). When cells were treated with AMD, both OGA and
OGT mRNA levels were dramatically decreased compared to con-
trol (Figures 4A,B). Combination of AMD and TMG did not
change the OGA and OGT mRNA levels compared to AMD treat-
ment only (Figures 4A,B). The same results were observed when
using K562 cells (Figures 4C,D).
RNA POL II OCCUPANCY IS DECREASED AT OGA TSS AFTER 48 H TMG
TREATMENT
We next investigated RNA Pol II occupancy at the OGA TSS via
RNA Pol II ChIP. In control K562 cells, RNA Pol II was bound to
OGA TSS with little binding upstream (−1000) or downstream
(+2700) of the TSS. However, after 48 h TMG treatment, RNA Pol
II occupancy was decreased at the OGA TSS compared to control
cells (Figure 5A). Normal mouse IgG ChIP was used as a negative
control (Figure 5B).
DISCUSSION
The production of UDP-GlcNAc, the substrate for OGT, integrates
various metabolic substrates allowing theO-GlcNAc modification
to act as a nutrient sensor (4, 27). Consequently, cells are sensitive
to changes in O-GlcNAc levels due to nutritional and metabolic
flux and will adjust cellular functions accordingly. Prolonged alter-
ations in homeostatic levels of O-GlcNAc will cause the protein
expression of OGT and OGA to change in an effort to restore
O-GlcNAc homeostasis (4). Exactly how cells sense alterations
to homeostatic levels of O-GlcNAc and adjust OGT and OGA
expression to compensate for the changes in O-GlcNAcylation is
unclear. For example, pharmacological inhibition of OGA rapidly
increases cellular O-GlcNAc levels; however, the protein expres-
sion of OGA will also increase in response to the elevation of
O-GlcNAc (13, 24). We sought to explore the mechanism as to
how OGT and OGA protein expression changes in response to
alterations in cellular O-GlcNAc levels. In agreement with previ-
ous reports, we found an increase in OGA protein expression as
quickly as 8 h in HeLa cells and 24 h in K562 and SY5Y cells after
treatment with TMG. OGT protein expression also decreased in
these later time points (Figure 1). Due to the fact that increased
levels of O-GlcNAc can increase the stability of proteins, such as
p53 (28) and TET (ten-eleven translocation) (29), we postulated
that increased O-GlcNAc could stabilize OGA. K562 or HeLa cells
exposed to CHX in the presence of TMG showed no difference
in the stability of either OGT or OGA (Figure 2) suggesting that
the increase in OGA protein expression was not due to increased
stability and more likely to an increase of OGA transcripts.
Importantly, decreased O-GlcNAc levels do not necessarily
increase OGT levels in all cell types; for example, blocking GFAT
(glutamine fructose-6-phosphate amidotransferase) activity with
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FIGURE 2 |TMG does not stabilize OGA protein. (A) HeLa cells and (B) K562 cells were treated with TMG, CHX (protein translation inhibitor), and
CHX+TMG. Cells were lysed, overall O-GlcNAc level, OGA and OGT protein level were analyzed by western blot, with actin as loading control.
FIGURE 3 | OGA mRNA level was increased afterTMG
treatment. After TMG treatment, relative OGA mRNA level in
(A) SH-SY5Y, (B) HeLa, and (C) K562 cells, as well as OGT mRNA
level in (D) SH-SY5Y, (E) HeLa, and (F) K562 cells was analyzed by
qPCR. (G) OGA mRNA level and (H) OGT mRNA level in SH-SY5Y
cells infected with GFP, OGT, and OGA adenovirus at 75 MOI for
24 h, respectively, were also analyzed by qPCR. Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) was served as internal
control. *P <0.05. **P < 0.01, compared with control (TMG 0 h or
GFP), n=3, Student’s t -test.
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FIGURE 4 |TMG does not stabilize OGA mRNA. HeLa cells
(A,B) and K562 cells (C,D) were treated with TMG, AMD (RNA
transcription inhibitor), and AMD+TMG, respectively. (A) OGA
(A,C) and OGT (B,D) mRNA level were analyzed by qPCR, with HPRT
as internal control. *P <0.05. **P <0.01, compared with control,
n=3, Student’s t -test.
FIGURE 5 | RNA Pol II occupancy at OGATSS was decreased after 48 h
TMG treatment in K562 cells. (A) RNA Pol II ChIP assay was performed on
control and 48 h TMG treated cells. ChIP DNA was analyzed by qPCR using a
set of primer targeting 1000 bp upstream of OGA TSS (−1000), OGA TSS (0),
and +700 bp downstream of OGA TSS (+2700). *P <0.05, n=3, Student’s
t -test. (B) Normal mouse IgG ChIP served as a negative control.
6-diazo-5-oxo-l-norleucine (DON) in HeLa cells lowered O-
GlcNAc levels but did not increase OGT protein expression (13).
On the other hand, OGA protein levels quickly decreased after
Cre-mediated knockout of OGT in mouse embryonic fibrob-
lasts (14), but OGA knockdown in colon cancer cells did not
significantly decrease OGT protein expression (30). Changes in
OGA protein expression appear more sensitive to changes in O-
GlcNAc than OGT in HeLa cells, while both OGT and OGA
expression significantly changed in SY5Y cells (Figure 1). Over-
expression of OGA did not substantially influence OGT protein
expression (Figure 1), and OGT overexpression did not change
OGA expression (Figure 1). Recently, the development of a selec-
tive OGT inhibitor allowed for a dramatic reduction in cellular
O-GlcNAcylation (31), which in turn caused OGA protein expres-
sion to rapidly decrease with only a minimal increase in OGT
protein expression (31). The dynamic change in OGA protein
expression was seen in the development of disease as well. In
red blood cells of prediabetic individuals, OGA expression was
significantly increased (32), and OGA protein levels correlated
with increased blood glucose in these prediabetic patients. These
data suggest that higher blood glucose levels promote increased
flux through the hexosamine biosynthetic pathway leading to ele-
vated OGT activity, followed by OGA protein levels increasing to
restore cellular O-GlcNAc homeostasis in erythrocyte precursor
cells. Together, these data support the proposed hypothesis that
if OGT acts as a nutrient sensor allowing for rapid changes in
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O-GlcNAcylation due to alterations, the cellular concentration of
UDP-GlcNAc (33), then OGA should be less sensitive to nutrient
changes and more sensitive to changes in O-GlcNAcylation.
In order to respond to changes in O-GlcNAc levels, cells rapidly
and dramatically alter the expression of OGA mRNA (Figure 3).
In the case of OGT, we did not detect a significant change in OGT
mRNA levels after TMG treatment. The rapid increase in OGA
mRNA levels after TMG treatment would argue that either OGA
transcripts were more stable or transcriptional activity at the OGA
promoter was increasing. We tested transcript stability by inhibit-
ing RNA polymerase II with AMD (21). Interestingly, OGA and
OGT transcript levels were not more stable after TMG treatment
in the presence of AMD (Figure 4) suggesting that the increase in
OGA mRNA levels with TMG was due to an increase in OGA gene
transcription.
Next, we performed ChIP at the OGA promoter with an anti-
body that recognized all forms of RNA Pol II (phosphorylated and
non-phosphorylated forms). After 48 h of prolonged TMG treat-
ment in K562 cells, total RNA Pol II at the promoter was decreased
compared to the control samples (Figure 5). Potentially, an anti-
body directed against the actively transcribing phosphorylated
C-terminal domain (CTD) of RNA Pol II might have demon-
strated an increase in enrichment of the phosphorylated forms of
RNA Pol II at the promoter while non-phosphorylated forms of
RNA Pol II would be less associated with the promoter. Interest-
ingly, RNA Pol II is O-GlcNAcylated on the CTD at the fourth
position of the CTD repeat, which is between the two activating
phosphorylations at serine two and serine five on the CTD,which is
needed for transcriptional elongation (34). BothO-GlcNAcylation
and phosphorylation appeared to be mutually exclusive suggest-
ing a cycle of O-GlcNAcylation and phosphorylation on the CTD
repeats (35). Several groups have suggested that OGT and OGA
work together to promote gene transcription by organizing the
RNA Pol II preinitiation complex (PIC) (11, 36).O-GlcNAcylation
was shown to promote the formation of the PIC in an in vitro tran-
scription assay system; however, OGA activity was required for full
transcriptional activation suggesting that OGT modified RNA Pol
II, which initiated the formation of the PIC, while OGA was then
required to remove the O-GlcNAc on the stalled RNA Pol II allow-
ing for phosphorylation and transcription elongation (11). We
have yet to explore RNA Pol II occupancy at the OGA promoter
after a short TMG treatment (for example 6 h), which might yield
a different result and needs to be studied further. The mRNA levels
of OGA in K562 cells did begin to decrease at the 48 h TMG treat-
ment suggesting that the OGA promoter might become inactive
after prolonged TMG treatment. Reciprocal binding of OGT and
OGA at active gene promoters provides several interesting future
questions into the nature of transcriptional regulation, and the
control of both the OGT and OGA promoter might be regulated
in this manner.
Many transcription factors are modified byO-GlcNAc (15) and
likely alteration of the O-GlcNAcylation level of a transcription
factor could mediate the change in OGA transcription. We used
the predictive software TFSEARCH (http://www.cbrc.jp/research/
db/TFSEARCH.html) to identify potential transcription factor-
binding sites in the first 1000 base pairs upstream of the OGA
TSS (37). Among the transcription factor-binding sites in this
sequence, GATA and MZF were the most predicted transcription
factors. Due to the essential and ubiquitous expression of OGA
(4), we anticipated that several housekeeping transcription fac-
tors might bind to this region, but we found only few of these.
Interestingly, both GATA and MZF are important transcription
factors regulating hemopoietic development (22, 38). Perhaps the
increased in OGA expression in prediabetic red blood cells (32)
was partially due to changes in either of these two proteins. O-
GlcNAcylation changes might lead to alteration of GATA or MZF
occupancy at the OGA promoter. Some GATA family members
are modified by O-GlcNAc (39); thus, this presents an interesting
avenue to explore in more detail.
Together, our data demonstrate that OGA protein and mRNA
expression is sensitive to cellular levels of O-GlcNAc. Some dis-
ease states have OGA expression uncoupled from O-GlcNAc
levels (40). In many different cancers, O-GlcNAc homeostasis
appears to be disrupted with increased OGT protein expression
and O-GlcNAc levels (41). Several pancreatic cancer cell lines
have increased O-GlcNAc levels when compared to an immor-
talized control cell line; importantly, OGT protein expression
was increased while OGA protein expression was decreased (40).
The uncoupling of OGA expression to O-GlcNAc homeostasis
could be an indicator of cancer progression and suggest that an
increase of OGA protein expression would be beneficial therapeu-
tically. Determining howO-GlcNAc regulates OGA expression and
transcription will be crucial for understanding the biology of O-
GlcNAcylation and how O-GlcNAc homeostasis is disrupted in
disease.
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